SPTBN2 and Marfan syndrome: In the nonseizure group, the yield was 44% (4/9), including one with SCN2A with autism, one FBN1 with Marfan syndrome, one DMD with muscle dystrophy, and one SPTBN2 with spinocerebellar ataxia.